KR20240006600A - 투약 요법 - Google Patents

투약 요법 Download PDF

Info

Publication number
KR20240006600A
KR20240006600A KR1020237041919A KR20237041919A KR20240006600A KR 20240006600 A KR20240006600 A KR 20240006600A KR 1020237041919 A KR1020237041919 A KR 1020237041919A KR 20237041919 A KR20237041919 A KR 20237041919A KR 20240006600 A KR20240006600 A KR 20240006600A
Authority
KR
South Korea
Prior art keywords
asciminib
imatinib
administered
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041919A
Other languages
English (en)
Korean (ko)
Inventor
스테파니 카이 도드
플로렌스 호우르카데-포텔레레트
펠릭스 후트
미셸 퀸란
줄리아 잭
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20240006600A publication Critical patent/KR20240006600A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237041919A 2021-05-11 2022-05-10 투약 요법 Pending KR20240006600A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187023P 2021-05-11 2021-05-11
US63/187,023 2021-05-11
PCT/IB2022/054321 WO2022238884A1 (en) 2021-05-11 2022-05-10 Dosing regimens

Publications (1)

Publication Number Publication Date
KR20240006600A true KR20240006600A (ko) 2024-01-15

Family

ID=81846537

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041919A Pending KR20240006600A (ko) 2021-05-11 2022-05-10 투약 요법

Country Status (8)

Country Link
US (1) US20240245666A1 (https=)
EP (1) EP4337205A1 (https=)
JP (1) JP2024518426A (https=)
KR (1) KR20240006600A (https=)
CN (1) CN117396202A (https=)
CA (1) CA3218550A1 (https=)
IL (1) IL308095A (https=)
WO (1) WO2022238884A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120239604A (zh) * 2023-11-01 2025-07-01 深圳市塔吉瑞生物医药有限公司 治疗白血病的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161416A1 (es) * 2012-05-15 2017-01-08 Novartis Ag Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1

Also Published As

Publication number Publication date
CN117396202A (zh) 2024-01-12
EP4337205A1 (en) 2024-03-20
WO2022238884A1 (en) 2022-11-17
US20240245666A1 (en) 2024-07-25
CA3218550A1 (en) 2022-11-17
JP2024518426A (ja) 2024-05-01
IL308095A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
US9585893B2 (en) Flumazenil complexes, compositions comprising same and uses thereof
Satoskar et al. Pharmacology and pharmacotherapeutics
JP7739256B2 (ja) 鎮静作用のないデクスメデトミジン治療レジメン
JP6448001B2 (ja) 液体配合剤
EP4076419A1 (en) Treatment of amyotrophic lateral sclerosis and related disorders
US20070105869A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
US20190008868A1 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CA3230291A1 (en) Dosing regimens associated with extended release paliperidone injectable formulations
AU2022376535A1 (en) Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
JP5362151B2 (ja) Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
TW200815014A (en) Method of improved diuresis in individuals with impaired renal function
WO2013059676A1 (en) Compositions for reduction of side effects
BRPI0616659A2 (pt) droga terapÊutica antituberculose, medicamento, e, kit para o tratamento de tuberculose
US20240245666A1 (en) Dosing regimens
CN110573148A (zh) 特发性肺纤维化的治疗
US20220168307A1 (en) Treatment of sma
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
KR20240091327A (ko) 복셀로터를 사용한 겸상 적혈구 질환의 치료 방법
US20050203105A1 (en) Composition and method for controlling alcohol-induced facial flushing in susceptible humans
CN110339195A (zh) 用于治疗胆管癌的喹啉衍生物
CN108478581A (zh) 防治运动病、梅尼埃病的药物及托伐普坦的医药用途
WO2024054412A1 (en) Methods and compositions for treating amyotrophic lateral sclerosis
TW202604485A (zh) 患有肝損傷患者肝疾病之治療
WO2025110992A1 (en) Method of administering belumosudil for patient subpopulations with hepatic impairment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231205

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250508

Comment text: Request for Examination of Application